Identification of senescence-related molecular subtypes and key genes for prostate cancer

Wei, Qiang; Yang, Lu; Feng, Dechao; Zhu, Weizhen; Shi, Xu; Xiong, Qiao; You, Jia

doi:10.4103/aja202258

Cited by 15 publications

(11 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study also demonstrates a correlation between age and TGM1 expression. Aging is a well-known risk factor for various tumors, as it results in reduced cell proliferation, homing, and differentiation processes (Feng et al 2023 ; Hu et al 2022 ; Feng et al 2020 ). These abnormalities in the human body contribute to the promotion and development of tumors (Ruiz et al 2023 ).…”

Section: Discussionmentioning

confidence: 99%

A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer

Wu,

Li,

Zhang

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment. Method Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method. Results TGM1 is expressed differently in various tumors and normal samples and is associated with the overall survival and progression-free time of KIRC, ACC, SKCM, LIHC, and STES. In LICH, we found a negative correlation between TGM1 expression and 6 indicators of tumor stemness. The mutation frequencies of BLCA, LIHC, and KIRC were 1.7%, 0.3%, and 0.3% respectively. In BLCA and BRCA, there was a significant correlation between TGM1 expression and the infiltration of CD4 + T cells, CD8 + T cells, neutrophils, and dendritic cells. Conclusion TGM1 has the potential to serve as both a prognostic marker and a drug target.

show abstract

Section: Discussionmentioning

confidence: 99%

A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer

Wu,

Li,

Zhang

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…An increasing number of studies showing links between PCa and aging [ 1 , 8 , 14 , 15 , 32 , 53 ]. Senescent cells can also inhibit carcinogenesis, promote tumor growth, recurrence, and PCa metastasis in advanced stages [ 54 , 55 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of senescence-related lncRNA prognostic index correlating with prognosis and radiosensitivity in prostate cancer patients

Feng,

Li,

Shi

et al. 2023

Aging

Self Cite

View full text Add to dashboard Cite

Background: An increasing number of studies are shown how crucial a role cellular senescence plays in tumor development. In this study, we developed a senescence-related lncRNA prognostic index (SRLPI) to forecast radiosensitivity and the probability of biochemical recurrence (BCR) in patients with prostate cancer (PCa). Methods: PCa cohorts in TCGA and GEO databases were downloaded. Senescence-and prognosis-related lncRNA with differential expression in tumor and normal samples were identified and used to establish the SRLPI score. Mutation landscape, function pathway, tumor stemness and heterogeneity and tumor immune microenvironment were also analyzed. We performed the analysis using R 3.6.3 and the appropriate tools. Results: A SRLPI score was constructed based on SNHG1 and MIAT in the TCGA cohort. Our classification of PCa patients into high- and low-risk groups was based on the median SRLPI score. When compared to the low-SRLPI group, the high-SRLPI group was more vulnerable to BCR (HR: 3.33). In terms of BCR-free survival and metastasis-free survival, the GSE116918 showed similar findings. Surprisingly, the SRLPI score demonstrated a high level of radiosensitivity for diagnosis (AUC: 0.98). Age, Gleason score, T stage, N stage, positive lymph nodes, and residual tumor were all significantly greater in patients with high SRLPI scores. Furthermore, this score was significantly related to markers of senescence. Protein secretion and androgen response were found to be substantially enriched in the low-SRLPI group, whereas E2F targets were found to be strongly enriched in the high-SRLPI group for pathway analysis. For the tumor microenvironment assessment, B cells, CD8+ T cells, immune score and TIDE score were positively related to SRLPI score while endothelial level was negatively associated with SRLPI score with statistical significance. Conclusions: We developed a SRLPI score that was related to prognosis and radiosensitivity and might be helpful in clinical practice.

show abstract

“…Aging is an unavoidable process of human and has different characteristics compared with young stage [28,92]. The incidence rate of cancer usually increases with aging [93,94]. Meanwhile, the world is entering an era of aging population [95].…”

Section: Conclusion and Perspectivementioning

confidence: 99%

Chronobiology of the Tumor Microenvironment: Implications for Therapeutic Strategies and Circadian-Based Interventions

Li,

Yu,

et al. 2024

Aging and disease

View full text Add to dashboard Cite

Numerous research works have emphasized the critical role that circadian rhythm plays in the tumor microenvironment (TME). The goal of clarifying chrono-pharmacological strategies for improving cancer treatment in clinical settings is a continuous endeavor. Consequently, to enhance the use of time-based pharmaceutical therapies in oncology, combining existing knowledge on circadian rhythms' roles within the TME is essential. This perspective elucidates the functions of circadian rhythms in the TME across various stages of cancer development, progression, and metastasis. Specifically, aging, angiogenesis, and inflammation are implicated in modulating circadian rhythm within the TME. Furthermore, circadian rhythm exerts a profound influence on current cancer treatments and thereby generates chronotheray to manage tumors. From a TME perspective, circadian rhythm offers promising opportunities for cancer prevention and treatment; nevertheless, further study is needed to address unanswered scientific problems.

show abstract

Identification of senescence-related molecular subtypes and key genes for prostate cancer

Cited by 15 publications

References 46 publications

A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer

A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer

Identification of senescence-related lncRNA prognostic index correlating with prognosis and radiosensitivity in prostate cancer patients

Chronobiology of the Tumor Microenvironment: Implications for Therapeutic Strategies and Circadian-Based Interventions

Contact Info

Product

Resources

About